Boston Scientific MultiSENSE Study On HeartLogic Positive
Zacks Investment Research | Sep 19, 2017 10:37PM ET
Boston Scientific (NYSE:BSX) announced positive clinical trial data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study. This study (based on 900 patients) was conducted to examine the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure (HF) decompensation.
The study demonstrated that HeartLogic Diagnostic iincreases the ability to classify patients at high or low-risk of experiencing a future HF event. Presently, physicians recommend blood test to diagnose HF or determine disease severity. However, this method is less reliable as the assessment loses relevance when patients’ conditions change. The MultiSENSE trial data showed that HeartLogic Diagnostic expanded the ability of a baseline blood test to identify patients at a high risk of a HF event.
Notably, the HeartLogic Diagnostic is already CE Marked and FDA approved and will be available commercially later this year under the Rhythm Management segment.
In the last reported second quarter, Rhythm Management was the second largest contributor to Boston Scientific's top line, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. CRM reflected a 2% year-over-year increase in sales in the reported quarter.
According to a report by GlobalData, the heart failure market is estimated to reach a value of $11.8 billion by 2025, at a CAGR of 13.7%. Considering the huge potential of the market, we believe the latest development is a strategic fit.
Over the past year, Boston Scientific has been trading above the broader Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.